SF3B1 and myelodysplastic syndrome: Within the different MDS entities SF3B1 mutations were favorable in MDS-RS-SLD (median OS: 106 vs. 25 months; p = 0.009), MDS-RS-MLD (median: 82 vs. 64 months; p = 0.049) and MDS-EB-2 (median: 129 vs. 25 months; p = 0.011), but were associated with a shorter OS in MDS 5q- (median: 69 vs. 79 months; p = 0.044) (Fig. 1E–I).